Olmesartan and intestinal adverse effects in the ROADMAP study

Mayo Clin Proc. 2012 Dec;87(12):1230-1; author reply 1232. doi: 10.1016/j.mayocp.2012.10.005.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / adverse effects*
  • Diarrhea / chemically induced*
  • Female
  • Humans
  • Imidazoles / adverse effects*
  • Intestines / pathology*
  • Male
  • Stomach / pathology*
  • Tetrazoles / adverse effects*

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Imidazoles
  • Tetrazoles